Nuclear Dbf2-related protein kinases (NDRs) in isolated cardiac myocytes and the myocardium: activation by cellular stresses and by phosphoprotein serine-/threonine-phosphatase inhibitors by Fuller, Stephen John et al.
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
1
Nuclear Dbf2-related protein kinases (NDRs) in isolated cardiac
myocytes and the myocardium: Activation by cellular stresses and
by phosphoprotein serine-/threonine-phosphatase inhibitors
Stephen J. Fullera Sampsa Pikkarainena, El Li Thama, Timothy E. Cullingforda, 
Jeffery D. Molkentinb, Hauke Cornilsc, Alexander Hergovichc, Brian A.
Hemmingsc, Angela Clerka, and Peter H Sugdena*
a
National Heart and Lung Institute (NHLI) Division, Faculty of Medicine, Imperial College
London, Flowers Building, Armstrong Road, London SW7 2AZ, UK
b
Department of Pediatrics, University of Cincinnati, Cincinnati Children's Hospital Medical
Center, 3333 Burnet Ave., Cincinnati, Ohio 45229-3039, USA
c
Friedrich Miescher Institute for Biomedical Research, Maulbeerstrasse 66, CH 4002 Basel,
Switzerland
Running title: Nuclear Dbf2-related protein kinases in the heart
* Corresponding author.  NHLI Division, Faculty of Medicine, Imperial College London,
Flowers Building (4th Floor), Armstrong Rd., London SW7 2AZ, UK.  Tel.: +44 20 7594
3410;  fax: +44 20 7594 3419.
E-mail address: p.sugden@imperial.ac.uk (P.H. Sugden).
* Manuscript
Click here to view linked References
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
2
Abstract
The nuclear Dbf2-related protein kinases 1 and 2 (NDR1/2) are closely-related AGC
family kinases that are strongly conserved through evolution.  In mammals, they are activated
inter alia by phosphorylation of an hydrophobic domain threonine-residue [NDR1(Thr-
444)/NDR2(Thr-442)] by an extrinsic protein kinase followed by autophosphorylation of a
catalytic domain serine-residue [NDR1(Ser-281)/NDR2(Ser-282)].  We examined NDR1/2
expression and regulation in primary cultures of neonatal rat cardiac myocytes and in
perfused adult rat hearts.  In myocytes, transcripts for NDR2, but not NDR1, were induced by
the hypertrophic agonist, endothelin-1.  NDR1(Thr-444) and NDR2(Thr-442) were rapidly
phosphorylated (maximal in 15 - 30 min) in myocytes exposed to some phosphoprotein Ser-
/Thr-phosphatase 1/2 inhibitors (calyculin A, okadaic acid) and, to a lesser extent, by
hyperosmotic shock, low concentrations of H2O2, or chelerythrine.  In myocytes adenovirally-
transduced to express FLAG-NDR2 (which exhibited a mainly-cytoplasmic localisation), the
same agents increased FLAG-NDR2 activity as assessed by in vitro protein kinase assays,
indicative of FLAG-NDR2(Ser-282/Thr-442) phosphorylation.  Calyculin A-induced
phosphorylation of NDR1(Thr-444)/NDR2(Thr-442) and activation of FLAG-NDR2 were
inhibited by staurosporine, but not by other protein kinase inhibitors tested.  In ex vivo rat
hearts, NDR1(Thr-444)/NDR2(Thr-442) were phosphorylated in response to ischaemia-
reperfusion or calyculin A.  From a pathological viewpoint, we conclude that activities of
NDR1 and NDR2 are responsive to cytotoxic stresses in heart preparations and this may
represent a previously-unidentified response to myocardial ischaemia in vivo.
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1.  Introduction
The nuclear Dbf2-related protein kinases (NDRs) are members of the AGC protein
serine-/threonine-kinase family and are strongly conserved between species as diverse as
yeasts and Homo sapiens [1,2].  Human (and mouse) cells express two isoforms encoded by
separate genes, namely NDR1 (or serine-/threonine kinase 38, STK38) and NDR2 (or serine-
/threonine kinase 38-like, STK38L) [1,2].  These cells also express two NDR1-/NDR2-
related protein kinases, large tumour suppressor-1 (LATS1) and LATS2 [1,2].  The NDRs are
widely-expressed in mouse [3] and human [4,5] tissues.  In mouse, NDR1 transcripts are
most-highly expressed in spleen and are also moderately expressed in brain, lung, thymus,
testis and adipose tissue whereas NDR2 transcripts are most-highly expressed in the
gastrointestinal tract (large and small intestine, stomach) and moderately expressed in testis
[3].  The heart also expresses NDR1 and NDR2 transcripts, albeit at lower levels [3].  In
human tissues, NDR1 and NDR2 are most highly expressed in thymus [4].  NDR1 is also
highly expressed in human skeletal muscles whereas NDR2 is highly expressed in heart and
brain [4].  It is not known whether these apparent differences in expression profiles between
mouse and Homo sapiens are real or reflect inter-laboratory variations.  The consensus
sequence phosphorylated by this group of kinases has been variously reported to be
(K/R)XX(S/T) (human NDR1 [6]), RXXS (preferred to RXXT) (yeast Dbf2 [7]) or
HX(R/H/K)XX(S/T) (human LATS1 [8]).  The physiological functions of the NDRs in
mammals are obscure.  NDR2 may be involved in the organisation of the actin cytoskeleton
in pheochromocytoma 12 (PC12) cells and its transcript is also rapidly but transiently induced
in mouse amygdalae following Pavlovian fear conditioning training [9].  Recently,
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NDR1/NDR2 have been implicated  in centrosome duplication with overexpression inducing
centrosome overduplication [10].
In their inactive state, NDRs are autoinhibited by an insert between the catalytic
domain subdomains VII and VIII (the autoinhibitory sequence) that is rich in basic residues
[11] and was originally thought to represent a nuclear localisation signal [5].  Activation of
NDRs involves regulatory phosphorylations and/or interactions with other proteins.  As with
many AGC kinases, NDRs are phosphorylated on two conserved residues, one in the C-
terminal hydrophobic domain (Thr-444 in human, mouse or rat NDR1, Thr-442 in human or
mouse NDR2) and one in the activation loop (or T loop) of the catalytic domain (Ser-281 in
human, mouse or rat NDR1, Ser-282 in human or mouse NDR2) [3,12].  One protein kinase
which phosphorylates NDR1(Thr-444)/NDR2(Thr-442) is the mammalian serine-/threonine-
STE20-like kinase 3 (MST3) [13] with dephosphorylation catalysed by phosphoprotein
serine-/threonine-phosphatase (PPP) PP2A [3,12], now known as PPP2 .  In contrast (and
unusually for AGC kinases), phosphorylation of NDR1(Ser-281)/NDR2(Ser-282) is thought
to represent an autophosphorylation [3,13,14].  In addition, activation may involve
interactions with other proteins.  Initially, the S100 Ca2+ binding protein was thought to be of
major importance and to account for the Ca2+-sensitivity of NDR activation [3,6,14].  One
suggestion is that phosphorylation of NDR2(Thr-75) in a S100/Ca2+-dependent manner leads
to phosphorylation of NDR2(Thr-442) in the phospho-NDR2(Thr-75) [NDR2(PThr-75)]
species by an unknown kinase [14,15].  The NDR2(Ser-281) residue in the NDR2(PThr-
75/PThr-442) species is then autophosphorylated leading to activation [14,15].  However, the
emphasis has now switched to the Mps-one binder (MOB) proteins which interact with basic
residues in the N-terminal regulatory domains of the NDRs [4,11].  It is not entirely clear how
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MOB proteins activate NDRs.  One view is that they bring NDRs to the plasma membrane for
interaction with the upstream kinases for the hydrophobic domain phosphorylation, thus
allowing enhanced autophosphorylation of the activation loop [16].  However, other
mechanisms proposed are the release of the inhibition imposed by the autoinhibitory
sequence [11] or, in yeast, perturbation and disruption of inhibitory self-associations [17].
Our interests in NDRs were stimulated by the observation that a microarray screen of
the changes in transcript abundances following exposure of neonatal rat cardiac (ventricular)
myocytes to the Gq protein-coupled receptor agonist, endothelin-1 (ET-1), revealed that
NDR2 transcript abundances were increased >2-fold after 4 h [18].  In these cells, which
become terminally differentiated during the perinatal period and are thus unable to undergo
complete cycles of cell division, ET-1 is a powerful stimulator of hypertrophic growth, and
this response has pathophysiological relevance [19-21].  These effects of ET-1 are brought
about by rapid (within minutes) but transient activation of intracellular signalling pathways,
particularly the extracellular signal-regulated kinase 1/2 (ERK1/2) cascade [22,23], and rapid
but phasic activation of successive waves of gene expression, the earliest of which involve
expression of immediate early genes [18].  Many of the early changes in gene expression are
sensitive to inhibition of the ERK1/2 cascade [18,24].  Ultimately, these early changes lead to
expression of genes associated with the established hypertrophic response [25].  Here, we
have characterised the acute activation of NDRs in cardiac myocytes and have found that,
whilst the expression of NDR2 was stimulated by ET-1, their activities were stimulated by
cytotoxic interventions and particularly by PPP inhibitors.
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2.  Materials and methods
2.1.  Materials
With the exception of ET-1 (which was from Bachem.), biochemical reagents were
from Sigma-Aldrich, Calbiochem or Alexis/Axxora,  and laboratory chemicals were from
VWR.  Anti-NDR antibodies were raised to residues 59-86 of Homo sapiens NDR1 (for the
measurement of the total pool) [16], and to a phosphopeptide (residues 436-450)
encompassing NDR1(PThr-444) for measurement of the species phosphorylated in the
hydrophobic domain [14].  These antibodies also recognise human NDR2 and NDR2(PThr-
442), respectively [13].  Since rat NDR1 is identical to human NDR1 and rat NDR2 is
identical to human NDR2 in these immunogen regions, (see Supplementary Material, Fig. 1),
these antibodies should and do recognise rat NDR1 and rat NDR2.  Rabbit polyclonal anti-
OctA (FLAG®) Probe (D-8) (sc-807)  and mouse monoclonal anti-OctA (FLAG®) Probe (H-
6) (sc-7787) were from Santa Cruz Biotechnology.  Secondary antibodies and fluorescent
mounting medium were from Dako.  [-32P]ATP, rainbow molecular weight markers,
streptavidin-Texas red and Hyperfilm MP were from GE Healthcare.
2.2.  Primary culture of neonatal rat cardiac myocytes
Myocytes were dissociated from the ventricles of 1- to 3-day-old Sprague-Dawley rat
hearts by an adaptation of the method of Iwaki et al. [26] as previously described [27]. 
Unless stated otherwise, cells were plated in gelatin-coated Primaria culture dishes (BD
Biosciences) at a density of 2 × 106 cells/35 mm dish or 4 × 106 cells/60 mm for 18 h in 15%
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(v/v) foetal calf serum. Unless experiments involved adenoviral infection, serum was
withdrawn for the 24 h before experimentation.
2.3.  Infections with adenoviral vectors
Details of the construction of the adenoviral vectors (Adv) encoding rat N-terminally
FLAG-tagged wild-type NDR2 (FLAG-NDR2) and N-terminally FLAG-tagged NDR2-
PIFtide {rat NDR2(1-432), i.e. lacking the hydrophobic domain residues 433-464, with the
human PIFtide [3-phosphoinositide-dependent kinase 1 (PDK1) interacting fragment] from
protein kinase N2 (PKN2, residues 969-983) spliced to the C-terminus, FLAG-NDR2-
PIFtide} are provided in the ‘Supplementary Material’ section.  For Adv infections other than
those for immunofluorescence staining, serum was withdrawn from myocytes (2 × 106
cells/35 mm dish) for approximately 6 h before infection with Adv encoding FLAG-NDR2 or
FLAG-NDR2-PIFtide .  In initial experiments, the multiplicities of infection were titrated so
that the relative levels of expression of FLAG-NDR2 and endogenous NDR1/NDR2 were
similar, as assessed by immunoblotting using the rabbit polyclonal anti-NDR1/NDR2
antibody.  Likewise, the multiplicity of infection of Adv.FLAG-NDR2-PIFtide was adjusted
so that expression of FLAG-NDR2-PIFtide and FLAG-NDR2 was approximately equal as
shown using the rabbit polyclonal anti-FLAG antibody.  Myocytes were used for
experimentation (no change of medium) at 20 h after they had been infected.
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2.4.  Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and
immunoblotting
Following exposure to agonists, myocytes were washed twice with ice-cold
phosphate-buffered saline (PBS).  For whole cell extracts, myocytes were scraped into 150
l/dish of Buffer A [20 mM -glycerophosphate pH 7.5, 2 mM EDTA, 5 mM dithiothreitol
(DTT), 50 mM NaF, 0.2 mM Na3VO4, 2 M microcystin LR, 10 mM benzamidine, 300 M
phenylmethylsulphonyl fluoride (PMSF), 200 M leupeptin, 10 M
trans-epoxy-succinyl-l-leucylamido-(4-guanidino)-butane (E64), containing 1% (v/v) Triton
X-100].  Samples were incubated on ice for 10 min and then centrifuged (10,000 × g, 5 min,
4°C).  The supernatants were retained and protein contents measured by the Bradford assay
(BioRad) [28].  Samples were boiled with 0.33 vol of SDS-PAGE sample buffer [10% SDS
(w/v), 13% glycerol (v/v), 300 mM Tris–HCl pH 6.8, 130 mM DTT, 0.2% bromophenol blue
(w/v)].  Proteins (20 50 g/lane, but equal for each blot) were separated by SDS-PAGE
using 10% (w/v) resolving gels and 4% (w/v) stacking gels, and transferred to nitrocellulose
as described previously [29].  Non-specific binding sites were blocked with 5% (w/v) non-fat
milk powder in TBST [20 mM Tris–HCl pH 7.5, 137 mM NaCl, 0.1% (v/v) Tween 20].
Membranes were incubated (overnight, 4°C) with primary antibodies [1:300 for total
NDR1/NDR2 and for NDR1(PThr-444)NDR2(PThr-442)] diluted in TBST containing 5%
(w/v) bovine serum albumin.  The NDR1(PThr-444)NDR2(PThr-442) antibody in
TBST/albumin could be used repeatedly providing it was stored at 4°C in the interim. 
Membranes were washed in TBST, incubated (60 min, room temperature) with horseradish
peroxidase-conjugated secondary antibodies (1/5,000) in TBST containing 1% (w/v) nonfat
milk powder, and were then washed in TBST.  Bands were detected by enhanced
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chemiluminescence (Santa Cruz Biotechnology) using Hyperfilm MP and were quantified by
scanning densitometry.
2.5.  Assay of FLAG-NDR2 activity (immunoprecipitation kinase assays)
Myocytes were washed twice with ice-cold PBS and extracted into 100 l of Buffer B
[20 mM Tris-HCl pH 7.5, 10% (v/v) glycerol, 100 mM KCl, 5 mM MgCl2, 1 mM EDTA,
0.05 % (v/v) 2-mercaptoethanol, 5 mM DTT, 5 mM NaF, 0.2 mM Na3VO4, 2 M microcystin
LR, 300 M PMSF, 200 M leupeptin, 10 M E64, containing 1% (v/v) Triton X-100]. 
Samples were incubated on ice for 10 min and then centrifuged (10,000 × g, 5 min, 4°C). 
The supernatants were retained and samples were taken for immunoprecipitation (75 or 90%
of the supernatant used), protein determination by Bradford assay [28] and occasionally for
immunoblotting.  For immunoprecipitation, samples were added to Eppendorf tubes
containing 20 l of protein A-Sepharose (1:1 slurry in Buffer B) and 5 l of rabbit anti-FLAG
antibody that had been pre-incubated together overnight at 4°C with rotation.  Samples were
rotated overnight at 4°C and the pellets collected by centrifugation (10,000 × g, 1 min, 4°C). 
The pellets were washed three times in Buffer B (0.7 ml), once with kinase assay buffer (150
l, 20 mM Tris-HCl pH 7.5, 1 mM DTT, 1 M microcystin LR, 4 M leupeptin, 1 mM
benzamidine) and finally resuspended in 45 l of kinase assay buffer containing 1 mM
KKRNRRLSVA peptide substrate [6].  The recovery of FLAG-NDR2 or FLAG-NDR2-
PIFtide (estimated by immunoblotting using the monoclonal anti-FLAG antibody following
immunoprecipitation with the rabbit polyclonal anti-FLAG antibody) was about 75% of the
input.
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FLAG-NDR2 or FLAG-NDR2-PIFtide assays were initiated by the addition of 5 l of
1 mM [-32P]ATP(1 Ci/assay)/100 mM MgCl2 followed by incubation at 30°C for 30 min. 
Reactions were terminated by the addition of 5 l 0.5 M EDTA, pH7.5, followed by cooling
on ice.  Samples were centrifuged (10,000 × g, 1 min, 4°C) and duplicate samples (20 l) of
the supernatants were spotted onto P81 paper squares which were then washed in 75 mM
H3PO4 (4 × 15 min) on a rocking platform. Radioactivity was measured by erenkov
radiation counting.  Blanks (one with kinase assay buffer + [-32P]ATP/MgCl2 and one
involving assay of KKRNRRLSVA kinase activity with immunopreciptates from cells
infected with ‘empty’ FLAG-tag Adv) were routinely included.
2.6.  Ex vivo heart preparations
Hearts of female rats (279 ± 6 g body wt.) that had littered 7-10 days previously were
perfused retrogradely at 10 kPa with Krebs-Henseleit bicarbonate-buffered saline as described
previously [30].  In each set of experiments, following a 15 min retrograde stabilisation
perfusion, hearts were either (i) perfused retrogradely for a further 20 min, (ii) rendered
globally-ischemic for 10 min by occlusion of the aortic inflow, (iii) reperfused retrogradely
for 10 min following 10 min of global ischaemia, or (iv) perfused retrogradely with 40 nM
calyculin A for 5 min.  The hearts were then frozen between tongs cooled in liquid N2 and
powdered by grinding in a pestle and mortar cooled in liquid N2.
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2.7.  Immunofluorescence staining
Myocytes were cultured on glass coverslips [precoated with laminin (20 g/ml in
PBS) and 1% (w/v) gelatin] placed in 35 mm Primaria culture dishes at a density of 1.5 × 106
cells/dish for 18 h in the presence of 15% (v/v) foetal calf serum.  Myocytes were infected
with Adv.FLAG-NDR2 (as described under ‘Infection with adenoviral vectors’ above) for 16
h in serum-free medium.  The medium was discarded and the cells were washed with ice-cold
PBS (3 × 0.5 ml).  Cells were fixed in 4% (w/v) formaldehyde (10 min), permeabilised with
0.3% (v/v) Triton X-100 in PBS, and non-specific antibody binding was blocked with 10%
(w/v) horse serum in PBS containing 0.3% (v/v) Triton X-100.  FLAG-NDR2 was detected
by incubation of cells with mouse anti-FLAG antibody (1:25 dilution, 2 h, 37°C), a
biotinylated goat anti-mouse IgG secondary antibody (1:200 dilution, 30 min, room
temperature) and streptavidin-Texas Red (1:200 dilution, 30 min, room temperature). 
Sarcomeric structures were identified by FITC-phalloidin (1:100, 1 h, room temperature). 
Nuclei were stained with Hoechst 33258 (50 g/ml, 10 min, room temperature).  Cells were
washed with PBS (3 × 0.5 ml) between each incubation. Slides were mounted and examined
using a Zeiss Axioskop microscope with a 100× oil immersion objective and photographed
using a digital camera.
2.8.  Quantitative PCR (qPCR)
RNA was extracted and cDNA synthesised using reverse transcription as previously
described [31].  qPCR was performed using a Real-Time PCR System model 7500 (Applied
Biosystems).  Amplifications were carried out in optical 96-well reaction-plates (Applied
Biosystems) with each well containing 12.5 l of SYBR Green Jump Start Taq Readymix
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(Sigma Aldrich Chemical Co.), 5 l of oligonucleotide primers (5 pmol each of forward and
reverse primers) and 7.5 l of cDNA template (diluted 15-fold in water).  Details of the
primers used are given in Table 1.  qPCR analysis of Gapdh was performed as a control and
the relative quantification protocol was used.  PCR conditions for all primer pairs were 50°C
for 2 min, 95°C for 10 min (Jump-Start Taq polymerase activation step), followed by 40
cycles of 95°C for 15 s and 59°C for 60 s.  Following qPCR, dissociation curve analysis was
routinely performed to check for aberrant amplification products (e.g. primer-dimers).
2.9.  Calculation of results and statistical methods
Within a single experiment (i.e. a single preparation of cardiac myocytes), results are
expressed relative to the maximum signal for the quantified immunoblots or FLAG-NDR2
activities.  Statistical significance was tested using two-tailed Student’s t test for paired
samples or one-way ANOVA with Tukey’s multiple comparison test as appropriate.  A
statistically significant difference required that P<0.05.
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3.  Results
3.1.  Molecular cloning of rat NDR2 cDNA
In an Affymetrix rat 230 2.0 array screen of primary cultures of neonatal rat cardiac
myocytes exposed to ET-1 for 4 h, two probe-sets (1372955_at and 1383299_at) identified an
expressed sequence tag (EST) that was significantly upregulated to 2.28-fold (average of both
probe-sets) of the zero-time control [18].  A BLAST search revealed that this rat EST
corresponded to the mouse NDR2 nucleotide sequence.  Rat NDR2 cDNA was cloned as
described in ‘Supplementary Material’ and the sequence obtained (bases 1 - 2406) deposited
in Genbank (accession no. EF444939.1).  The translational open reading frame (bases 151 -
1542, 464 amino acids) was aligned against human, mouse and rat NDR1, and human and
mouse NDR2 using the ClustalW program (www.ebi.ac.uk/clustalw) (Supplementary
Material, Fig. 1).  The primary structure of rat NDR2 (calculated molecular mass: 53.6 kDa)
is identical to mouse NDR2 except for replacement of mouse Asn-15 and Val-216 with Ser-
15 and Ile-216, respectively, in rat NDR2.
Using qPCR, we verified that NDR2 mRNA was significantly upregulated (3- to 4-
fold of zero-time control) by ET-1 at 1.5 h and remained upregulated at this level until at least
8 h (Fig. 1A).  In contrast, NDR1 mRNA was not significantly altered over the same time
period (Fig. 1B).  However, using the antibody which recognises both NDR1 and NDR2, we
were unable to detect any change in the abundances of NDR proteins by ET-1 over the same
time period (results not shown).  The primary structures of NDR1 and NDR2 show a high
degree of identity (Supplementary Material, Fig. 1) and the proteins are very similar in
molecular mass (NDR1 is 54.0 kDa), so that it is possible that any newly-synthesised NDR2
would not necessarily be readily detectable against the pre-existing NDR1/NDR2
background.
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3.2.  Phosphorylation of NDR1(Thr-444)/NDR2(Thr-442) and activation of FLAG-NDR2 by
calyculin A
Calyculin A is an inhibitor of PPP1 and PPP2 (formerly known as PP2A), inhibiting
each approximately equipotently (Table 2).  Calyculin A (200 nM) induced a rapid
phosphorylation (detectable by 1 min) of NDR1(Thr-444)/NDR2(Thr-442) in cardiac
myocytes, reaching a maximum at 10  20 min and remaining stable for at least 90 min (Fig.
2A).  There was no change in total NDR1/NDR2 abundance (Fig. 2A).  Because of their
similarities in molecular mass, NDR1 and NDR2 usually co-migrate though, if samples are
electrophoresed for longer, occasionally two closely-migrating bands are detectable with the
antibody to NDR1(PThr-444)/NDR2(PThr-442).  Using this anti-phospho-NDR antibody, the
EC50 for the calyculin A-mediated phosphorylation of NDR1(Thr-444)/NDR2(Thr-442) was
computed to be approximately 10 nM (Fig. 2B).  The activation of NDR1 or NDR2 requires
dual phosphorylation of NDR1(Ser-281/Thr-444) or NDR2(Ser-282/Thr-442), the
phosphorylation of NDR1(Ser-281)/NDR2(Ser-282) representing autophosphorylations
following the NDR1(Thr-444)/NDR2(Thr-442) phosphorylations [3,13,14].  However, the
available antibody [14] raised against NDR1(PSer-281)/NDR2(PSer-282) is of relatively low
affinity/efficacy and we could not examine the phosphorylation of these sites.  We did
investigate whether, following adenovirally-mediated transfer of FLAG-NDR2, the activity of
FLAG-NDR2 as measured by immunoprecipitation kinase assays was commensurate with
phosphorylation of NDR1(Thr-444)/NDR2(Thr-442).  We adjusted the adenoviral infections
so that we achieved essentially equal expression of FLAG-NDR2 and endogenous
NDR1/NDR2 (Fig. 2C).  Immunprecipitation kinase assays using the anti-FLAG antibody
showed that, as for the phosphorylation of NDR1(Thr-444)/NDR2(Thr-442) (Fig. 2B), the
activity of FLAG-NDR2 was also stimulated by calyculin A with an EC50 of approximately
10 nM (Fig. 2D).  We noticed that calyculin A also appeared to be positively chronotropic in
these myocyte cultures and thus considered the possibility that contractile activity might be
responsible for NDR phosphorylation.  However, contractile arrest by blockade of the L-type-
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and T-type Ca2+ channels with 10 M nifedipine and 1.8 M mibefradil did not reduce the
effects of calyculin A (results not shown).
3.3.  Phosphorylation of NDR1(Thr-444)/NDR2(Thr-442) by hyperosmotic shock and
oxidative stress
Exposure of myocytes to hyperosmotic shock (0.5 M sorbitol) resulted in a rapid
(maximal in 10 min or less) phosphorylation of NDR1(Thr-444)/NDR2(Thr-442) (Fig. 3A)
though, unlike phosphorylation elicited by 200 nM calyculin A (Fig. 2A), phosphorylation
had declined by 90 min.  Oxidative stress (0.5 mM H2O2) caused a somewhat slower
phosphorylation (maximal at about 20 min) and this again declined by 90 min (Fig. 3B).  In
neither condition was there any change in the abundance of total NDR1/NDR2 (Fig. 3A-B). 
The phosphorylation elicited by oxidative stress was detectable at 0.1 mM H2O2 and showed a
distinct peak occurring at about 0.5 mM (Fig. 3C).  At higher concentrations (1 10 mM
H2O2), phosphorylation declined.  There were no losses of myocytes from the dishes at up to
3 mM H2O2, as shown by the immunoblots against total NDR1/NDR2 (Fig. 3C), though it is
possible that some losses occurred at 10 mM H2O2.
3.4.  Relative potencies of phosphorylation of NDR1(Thr-444)/NDR2(Thr-442) and activation
of FLAG-NDR2 by calyculin A, hyperosmotic shock and H2O2, and identification of
additional modulators
We examined the ability of a wide range of known modulators of myocardial
processes to mediate phosphorylation of NDR1(Thr-444)/NDR2(Thr-442) and/or activation
of FLAG-NDR2 (see Supplementary Material, Table 2 for details of agonists/interventions
without effect).  We also set any modulators identified as being effective in a hierarchy in
comparison with calyculin A.  Chelerythrine is allegedly a protein kinase C (PKC) inhibitor
[32], though this has been questioned at least in the case of the PKC isoform [33].  In
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cardiac myocytes, chelerythrine causes conventional and novel PKC-independent pyknosis,
shrinkage and death that may result from the induction of oxidative stress [34].  In
comparison with 200 nM calyculin A (NDR1/NDR2 control not subtracted), chelerythrine is
about 45 to 50% as effective in inducing phosphorylation of NDR1(Thr-444)/NDR2(Thr-442)
(Fig. 4A), but is only about 20% (control FLAG-NDR2 activity not subtracted) as effective in
inducing activation of FLAG-NDR2 (Fig. 4B).  Likewise, 0.5 mM H2O2 is about 40 to 45% as
effective as 200 nM calyculin A in inducing phosphorylation of NDR1(Thr-444)/NDR2(Thr-
442) but is only about 5 to 10% as effective in inducing activation of FLAG-NDR2 (Fig. 4A-
B).  The PPP2 inhibitor okadaic acid (OKA), which also inhibits PPP1 though less effectively
(Table 2), is known to induce phosphorylation and activation of NDR1/NDR2 [3,12].  In our
hands, after a 60 min incubation, 1 M OKA is almost as effective as incubation with 200
nM calyculin A for 20 or 60 min in inducing phosphorylation of NDR1(Thr-444)/NDR2(Thr-
442) (Fig. 4A).  However, following a 20 min incubation, 1 M OKA does not elicit any
statistically significant phosphorylation of NDR1(Thr-444)/NDR2(Thr-442) compared with a
control incubation (Fig. 4A), though there is a statistically-insignificant increase to about 30%
of the level observed with 200 nM calyculin A for 20 or 60 min.  For activation of FLAG-
NDR2, OKA (1 M, 20 min) was <10% as effective as calyculin A (200 nM, 20 min) (Fig.
4C).  However, after a 60 min incubation with OKA, this had increased to 45 to 50% (Fig.
4C).  The general conclusions are (i) calyculin A is the most powerful stimulator of
NDR1(Thr-444)/NDR2(Thr-442) and activation of FLAG-NDR2 that we have identified, (ii)
generally, activation of FLAG-NDR2 lags behind phosphorylation of NDR1(Thr-
444)/NDR2(Thr-442).  Because it could be argued that this difference was related to the
different species of NDRs examined (endogenous NDR1/NDR2 or FLAG-NDR2), we
examined the phosphorylation of endogenous NDR1/NDR2 and FLAG-NDR2 in FLAG-
NDR2-transduced cardiac myocytes (Fig. 4D).  This was feasible because of the lower
mobility of FLAG-NDR2.  No differences between the phosphorylation of endogenous
NDR1(Thr-444)/NDR2(Thr-442) and FLAG-NDR2(Thr-442) could be identified for any
agonist.  We also calculated the approximate ratio of expression of FLAG-NDR2(PThr-442)
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to endogenous NDR1(PThr-444)/NDR2(PThr-442) using the anti-NDR1(PThr-
444)/NDR2(PThr-442) antibody.  If it can be assumed that the most significant factor
influencing this ratio is the levels of expression, the value should approximate to the FLAG-
NDR2/endogenous NDR1/NDR2 ratio (Fig. 2C).  The FLAG-NDR2(PThr-442)/endogenous
NDR1(PThr-444)/NDR2(PThr-442) ratio is approximately 1.5, i.e. similar to that observed in
Fig. 2C.
Given that calyculin A is an equipotent PPP1/PPP2 inhibitor whereas OKA inhibits
PPP2 more potently (Table 2), the spectrum of NDR1/NDR2 phosphorylation (Fig. 4A,D)
and FLAG-NDR2 activation (Fig. 4C) suggests that the effects of calyculin A could be
exerted primarily through PPP1.  We therefore investigated the effects of tautomycetin (200
nM for up to 4 h) which is primarily a PPP1 inhibitor (Table 2) and fostriecin (200 nM for up
to 4 h) which is primarily a PPP2 inhibitor (Table 2) on activity of FLAG-NDR2.   Neither
inhibitor had any detectable effect (results not shown).  Furthermore, the potent PPP1/PPP2
inhibitor (Table 2), microcystin LR (2 M), did not activate FLAG-NDR2, nor did it induce
phosphorylation of endogenous NDR1(Thr-444)/NDR2(Thr-442) or FLAG-NDR2(Thr-442). 
The effects of PPP inhibitors on the NDRs are therefore limited largely to calyculin A, with
lesser effects of OKA.
3.5.  Inhibitors of calyculin A-mediated activation of FLAG-NDR2
We investigated the ability of a number of known protein kinase inhibitors to reduce
the activation of FLAG-NDR2 resulting from exposure of cardiac myocytes to 50 nM
calyculin A.  Of the inhibitors examined, the only inhibitor with any effect was staurosporine. 
Staurosporine was originally identified as a PKC inhibitor [35] but is now recognised to be a
non-selective protein kinase inhibitor [36] (see also Reference [33] for 7-
hydroxystaurosporine).  Staurosporine exhibited an IC50 of approximately 40 nM for the
inhibition of the activation of FLAG-NDR2 by 50 nM calyculin A (Fig. 5A).  This inhibition
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
19
was not attributable to ‘carry-over’ of staurosporine from the cell incubations into the assay
because addition of staurosporine up to 1 M for the last 5 min of a 20 min exposure of
myocytes to 50 nM calyculin A [i.e. after FLAG-NDR2 would have been essentially
completely activated by calyculin A (Fig. 2A) but prior to extraction and
immunoprecipitation] did not result in any significant reduction in FLAG-NDR2 activity.  It
is possible that staurosporine may not inhibit phosphorylation of NDR1(Thr-444)/NDR2(Thr-
442) but could selectively inhibit the autophosphorylation of NDR1(Ser-281)/NDR2(Ser-
282).  We therefore also examined its effects on the calyculin A-stimulated phosphorylation
of NDR1(Thr-444)/NDR2(Thr-442) and FLAG-NDR2(Thr-442) (Fig. 5B).  Staurosporine
also inhibited the calyculin A-stimulated phosphorylation of endogenous NDR1(Thr-
444)/NDR2(Thr-442) and of exogenous FLAG-NDR2(Thr-442) (Fig. 5B), and this in itself
should prevent phosphorylation of FLAG-NDR2(Ser-282) and its activation (Fig. 5A).  We
do not know whether staurosporine also inhibits the autophosphorylation of NDR1(PThr-
444)/NDR2(PThr-442) at the T loop residues.
The following were ineffective in inhibiting activation of FLAG-NDR2 by calyculin
A: 100 M genistein (a generalised Tyr-protein kinase inhibitor [37]), 10 M GF109203X
(generalised PKC inhibitor [38] which also inhibits a number of other protein kinases [33]),
20 M HA1077 (a PKN inhibitor [39] which inhibits a number of protein kinases including 
protein kinase A and Rho kinase [33]), 10  M SB203580 [inhibitor of the  and  isoforms
of p38-mitogen-activated protein kinase (p38-MAPK) [40]] or 10 M Y27632 (Rho kinase
inhibitor [41] which also inhibits PKN [33]).  Equally, no inhibitor activated FLAG-NDR2 in
the absence of calyculin A (results not shown).  The phosphoinositide 3-kinase (PI3K)
inhibitor, LY294002 [42] (50 M), did not inhibit NDR1(Thr-444)/NDR2(Thr-442)
phosphorylation or activation of FLAG-NDR2 (results not shown). [We ensured that the
LY294002 preparation used was active by demonstrating that it prevented stimulation of
protein kinase B/Akt (PKB/Akt) phosphorylation by 300 nM insulin.]
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3.6.  Activity of FLAG-NDR2-PIFtide
Mutation of the two phosphorylation sites in the catalytic and hydrophobic domains of
NDR1 (i.e. Ser-281 and Thr-444) to acidic residues is relatively-ineffective in producing a
kinase with increased constitutive activity [3].  A constitutively-activated species can be
produced by splicing NDR2(1-432) to PKN2(969-983) to produce NDR2-PIFtide, as has been
previously described for human NDR2 [3].  We examined the activities of FLAG-NDR2 (rat)
and  FLAG-NDR2-PIFtide (rat-human chimera) in the absence or presence of calyculin A and
approximately matching the abundances of FLAG-NDR2 and FLAG-NDR2-PIFtide (Fig. 6). 
After subtracting the activity seen following infection with the adenoviral blank (which was
not accurately matched for multiplicity of infection with Adv.FLAG-NDR2 and Adv.FLAG-
NDR2-PIFtide) and correcting for differences in relative abundance, the constitutive activity
of FLAG-NDR2-PIFtide was found to be approximately 10-fold greater than that of FLAG-
NDR2 (Fig. 6).  Not unexpectedly, FLAG-NDR2-PIFtide (which lacks the Thr-442
phosphorylation site) could not be activated by calyculin A (Fig. 6).
3.7.  Intracellular localisation of NDR2 in cardiac myocytes
Using the antibodies available, we were unsuccessful in staining for endogenous
dephospho-NDR (as were Hergovich et al. [16] in U2-OS cells), nor were we successful in
staining for phospho-NDRs.  We therefore examined the intracellular localisation of NDR2
by infecting myocytes with Adv.FLAG-NDR2 and staining for the FLAG epitope.  FLAG-
NDR2 localised to the cytoplasm in cardiac myocytes and was clearly excluded from the
nucleus (Fig. 7).  The pattern of staining was somewhat uneven in the cytoplasm and there
was a suggestion of some partition of NDR2 to the plasma membrane.  There was no
evidence of any change in localisation following exposure to 30 nM calyculin A for 20 min
(results not shown).
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3.8.  Phosphorylation of NDR1(Thr-444)/NDR2(Thr-442) in intact heart by calyculin A or by
ischaemia and reperfusion
Calyculin A proved to be the most powerful stimulator of NDR1(Thr-
444)/NDR2(Thr-442) phosphorylation and activator of FLAG-NDR2 in neonatal rat cardiac
myocytes that we identified here (see Fig. 4A-D).  Some of the interventions resulting in
phosphorylation of NDR1(Thr-444)/NDR2(Thr-442) and activation of FLAG-NDR2 in
myocytes are established cytotoxic stresses in neonatal cardiac myocytes (chelerythrine [34],
H2O2 [43] and hyperosmotic shock [44]).  However, it is important to show that these
findings are not confined to neonatal cells.  We therefore investigated the effects of calyculin
A and of pathologically-relevant cardiac stresses, namely ischaemia and ischaemia-
reperfusion in intact adult rat hearts.  As expected, calyculin A (40 nM, 5 min) induced a
highly-significant (P<0.0001) increase in the phosphorylation of NDR1(Thr-444)/NDR2(Thr-
442) in perfused hearts (Fig. 8).  Although there was some suggestion that global ischaemia
(10 min) increases phosphorylation of NDR1(Thr-444)/NDR2(Thr-442), this was not
significantly different from control normoxic perfusions.  In contrast, global ischaemia (10
min) followed by reperfusion (10 min) resulted in significant (P<0.0001) phosphorylation of
NDR1(Thr-444)/NDR2(Thr-442) which, after subtraction of the control, was equivalent to
about 30% of the level induced by 40 nM calyculin A for 5 min (Fig. 8).
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4. Discussion
4.1.  General comments
The NDRs are highly-conserved protein Ser-/Thr-kinases that are members of the
AGC kinase superfamily [1,2].  In terms of their activation, the current scheme is that
NDR1(Thr-444) and NDR2(Thr-442) (the hydrophobic domain residues) are first
phosphorylated by an upstream kinase and then NDR1(PThr-444) and NDR2(PThr-442) each
autophosphorylate their own T loop residues in their catalytic domains to produce the active
species NDR1(PSer-281/PThr-444) and NDR2(PSer-282/PThr-442) [1,2].  The fact that
activation of FLAG-NDR2 tends to lag behind phosphorylation of NDR1(Thr-
444)/NDR2(Thr-442) (for example, seen clearly for OKA in Fig. 4A, C) suggests that this
ordered phosphorylation occurs in cardiac myocytes.  The agonists that lead to activation of
NDRs are poorly-characterised and their biological functions in higher organisms are poorly-
understood.  Given that NDR1/NDR2 are highly-conserved through evolution, it seems likely
that they possess important functions. NDR2 may be involved in organisation of the actin
cytoskeleton [9] and, recently, a role for NDR1/NDR2 in centrosome duplication has been
identified [2,10].  Although populations of myocytes range from the mononucleate to the
multinucleate and thus must possess some capacity for karyokinesis, they are generally
considered to be terminally-differentiated and incapable of cytokinesis.  It therefore seems
unlikely that centrosome duplication is of major importance in their case.
4.2.  Expression of the NDR1 and NDR2 genes
At the level of mRNA, NDR2 transcripts are rapidly but transiently induced in
amygdalae of mice following emotional stress [9] and, here, we show that NDR2 mRNA is
also rapidly induced by ET-1 in neonatal rat cardiac myocytes (Fig. 1A).  In contrast, NDR1
mRNA is not induced by ET-1 (Fig. 1B).  Presumably, their promoter regions are sufficiently
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different to allow differential transcription or else transcript stability may be involved.  Using
microarrays (Affymetrix rat 230 2.0 array at 30 min or the more-restricted Affymetrix rat
U34A microarrays at 2 or 4 h) in conjunction with semi-quantitative PCR and/or qPCR, we
have shown that, for ET-1, the activation of the ERK1/2 cascade is required for the increased
expression of the majority of transcripts upregulated at 30 min , 2 h or 4 h [18,24].  We have
not yet studied in detail whether this is the case for NDR2 mRNA [the U34A microarrays did
not have a probe set for rat NDR2 [24] and we only studied the 30 min time point in our more
recent study [18] when NDR2 transcripts are not upregulated (Fig. 1A)].
4.3.  Involvement of PPPs in NDR phosphorylation and activation
The PPP superfamily, of which there are seven sub-families, is encoded by 20 genes
in Homo sapiens and these encode about 28 catalytic subunits [45].  There is also a
multiplicity of regulatory subunits (particularly for PPP1) which are involved in targeting (to
control subcellular localisation and substrate specificity) and regulation (e.g. inhibitory
subunits).  Previously, OKA has been identified as an agent that stimulates phosphorylation
and activation of NDR1/NDR2 [3,12].  This is presumably achieved by inhibiting a PPP,
allowing unknown NDR1/NDR2 kinases to phosphorylate NDRs.  Here, we show that, at
maximally-effective concentrations, calyculin A is more effective than OKA in inducing
NDR1(Thr-444)/NDR2(Thr-442) phosphorylation and activation of FLAG-NDR2 in neonatal
rat cardiac myocytes after 20 min (Fig. 4A, C).  Although calyculin A or OKA treatment
result in equivalent NDR1(Thr-444)/NDR2(Thr-442) phosphorylation after 60 min, activation
of FLAG-NDR2 with OKA is still less than with calyculin A (Fig. 4A, C).  A similar
hysteresis between phosphorylation of NDR1(Thr-444)/NDR2(Thr-442) and activation of
FLAG-NDR2 is seen in the individual comparisons of all interventions (Fig. 4).  It probably
reflects the ordered nature of the phosphorylation of first NDR1(Thr-444)/NDR2(Thr-442)
followed by NDR1(Ser281)/NDR2(Ser-282).  In previous work in which COS cells were
transfected with tagged NDRs, OKA (1 M, 60 min) stimulated NDR activity by 12- to 25-
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fold  [3,12].  This compares with 21-fold in our analogous experiments (Fig. 4C),  but we find
that calyculin A (200 nM, 60 min) stimulates activity by about 45-fold (Fig. 4C).  We do not
know whether these differences result from trivial causes (e.g. differences in permeability) or
whether there are mechanistic differences.  Importantly, calyculin A stimulates
phosphorylation of NDR1(Thr-444)/NDR2(Thr-442) in adult perfused heart (Fig. 8),
confirming that the findings in neonatal myocyte are not confined this particular stage of
maturation.
Though calyculin A and OKA may show differing selectivities for PPP1 and PPP2
[OKA has a 50-fold greater IC50 for PPP1 than PPP2 (Table 2)], they are both relatively
potent inhibitors of both PPPs at least in vitro (Table 2).  We had hoped possibly to
discriminate between PPP1 and PPP2 using the more selective inhibitors fostriecin and
tautomycetin (Table 2), and we also studied the effects of microcystin LR.  However, we
were never able to activate FLAG-NDR2 with these, nor did microcystin LR cause
phosphorylation of endogenous NDR1(Thr-444)/NDR2(Thr-442) or FLAG-NDR2(Thr-442). 
We do not understand the reasons for this.  They could be trivial (e.g. permeability), but all
ineffective inhibitors have been used in intact cell preparations previously.  Equally, there
may be PPP1/PPP2 holoenzyme species which are insensitive to fostriecin, tautomycetin or
microcystin LR, or there may be PPP species other than PPP1 and PPP2 which are sensitive
to calyculin A and OKA but which are not sensitive to fostriecin, tautomycetin or microcystin
LR.  Furthermore, it may be incorrect to assume that the actions of calyculin A or OKA are
exerted at the level of the PPP(s) directly responsible for deposphorylating NDRs.  The
point(s) of action could lie further upstream.  The current predominating view that PPP2 is
responsible for the dephosphorylation of NDR1(PSer-281/PThr-444) and NDR2(PSer-
282/PThr-442) is based on experiments in intact cells with OKA [3,12], and on in vitro
experiments involving dephosphorylation of NDR1(PSer-281/PThr-444) with recombinant
PPP2 [12].  However, the concentration of OKA used in these experiments was 1 M or 300-
times greater than the IC50 even for PPP1.  Whilst there may be unassessed permeability
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problems related to the access of OKA to the intracellular compartment, these experiments
are not unequivocal.  Equally, in vitro experiments with recombinant PPP2 are not
unequivocal because of the possibility that any PPP might dephosphorylate the phospho-
NDRs if present in high enough excess.  The PPP(s) responsible for dephosphorylating
NDR1(PSer-281/PThr-444) and NDR2(PSer-282/PThr-442) remain somewhat obscure.
4.4.  Phosphorylation and activation of NDR1/NDR2
Here, we have shown that NDR1/NDR2 are phosphorylated and activated by a variety
of stimuli in cardiac myocytes and intact heart.  Though we have not identified the kinases
responsible, these experiments show that the endogenous upstream signalling is intact.  With
respect to the established kinases, PDK1 is often involved in phosphorylation of a T loop Ser-
/Thr-residue in AGC kinases, i.e. a Ser-/Thr-residue in the catalytic domain [46,47]. 
Activation of PDK1, which is probably potentially active in the basal state by virtue of its
high affinity interactions with 3-phosphoinositides [48], is mediated by PI3K-dependent
phosphorylation of phosphatidylinositol 4,5-bisphosphate [PtdIns(4,5)P2] to PtdIns(3,4,5)P3
and lies downstream from the insulin or insulin-like growth factor 1 (IGF1) receptor protein
tyrosine kinases (RPTKs) as well as other RPTKs [47,49].  These T loop phosphorylations
are either regulatory (i.e. respond to external stimuli to change phosphorylation state and
activity of the kinase involved) or are essentially facilitative (i.e. are constitutive rather than
regulatory, but are necessary for activity).  Evidence has been presented that neither PDK1
nor insulin or IGF1 is involved in the regulation of NDR1 [12] though, equally, contradictory
evidence has been presented that IGF1-activated PDK1 is an NDR2(Thr-442) kinase and this
phosphorylation precedes the autophosphorylation of the T loop residue [15].  We did not
find any evidence that insulin (which does cause PI3K/PDK1-dependent phosphorylation of
PKB/Akt in cardiac myocytes [50]) stimulated phosphorylation of NDR1(Thr-
444)/NDR2(Thr-442) (Supplementary Material, Table 2A) nor did LY294002 inhibit the
phosphorylation of NDR1(Thr-444)/NDR2(Thr-442) or activation of FLAG-NDR2 by
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calyculin A.  Our data thus do not support a role for PDK1.  A second mode of activation
proposed by Suzuki et al. [15] involves a S100/Ca2+-dependent phosphorylation of
NDR2(Thr-75), then phosphorylation of NDR2(Thr-442) in the NDR2(PThr-75) species by
an unknown kinase, and finally autophosphorylation of NDR2(Ser-281) in the NDR2(PThr-
75/PThr-442) species leading to activation [14,15].  The necessary increase in Ca2+
concentrations is mediated through phospholipase C (PLC) and hydrolysis of PtdIns(4,5)P2
to the Ca2+-mobilising ‘second messenger’, inositol 1,4,5-trisphosphate [Ins(1,4,5)P3] [15]. 
However, in cardiac myocytes, platelet-derived growth factor stimulates PtdIns(4,5)P2
hydrolysis and Tyr-phosphorylation of PLC1 [50], but does not stimulate NDR1(Thr-
444)/NDR2(Thr-442) phosphorylation (Supplementary Material, Table 2A).  Furthermore,
ET-1 stimulates PLC-mediated hydrolysis of PtdIns(4,5)P2 in cardiac myocytes [51] but
does not stimulate phosphorylation of NDR1(Thr-444)/NDR2(Thr-442) or activation of
FLAG-NDR2 (Supplementary Material, Table 2A and 2B).
One upstream kinase that may be involved in the phosphorylation of NDR1(Thr-
444)/NDR2(Thr-442) is mammalian STE20-like kinase 3 (MST3) [13], also known as
STK24, a member of the germinal centre kinase family GCK-III subclass [52,53].  The
regulation of these kinases in terms of the agonists that lead to their activation is not well-
understood and indeed Pombo et al. [53] state that ‘To date, no stimuli have been shown to
activate MST3’.  In fact, like the NDRs, MST3 is activated by OKA [13] and calyculin A
[54].  Overexpression of MST3 in HEK293 cell causes fragmentation of DNA indicative of
apoptosis/cell death [55].  If the NDRs are involved, this would suggest that their activation
by MST3 should be pro-apoptotic.   It will be of interest to examine whether, in addition to 
calyculin A and OKA, pro-apoptotic stimuli such as chelerythrine, hyperosmotic shock and
H2O2 activate MST3.  One characteristic of the upstream NDR1(Thr-444)/NDR2(Thr-442)
kinase that we did identify is that it is inhibited by staurosporine (Fig. 5A-B).  Staurosporine
and its derivatives inhibit a broad spectrum of Ser-/Thr-protein kinases (including PDK1),
though a number of kinases are relatively insensitive [33,36].  A prerequisite of the
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NDR1(Thr-444)/NDR2(Thr-442) kinase is that its activity or activation should be inhibited
by staurosporine.
4.5.  Pathophysiological relevance of interventions which stimulate phosphorylation of
NDR1(Thr-444)/NDR2(Thr-442) and activation of FLAG-NDR2
The interventions which stimulate phosphorylation of NDR1(Thr-444)/NDR2(Thr-
442) and activation of FLAG-NDR2 most clearly are calyculin A and OKA (Fig. 2A-B, D,
Fig. 8) and OKA (Fig. 4A, C).  Other than possibly contributing to the understanding of
diarrhetic shellfish poisoning for which OKA is responsible, these findings have very little
pathophysiological significance.  The phosphorylation of NDR1(Thr-444)/NDR2(Thr-442)
and activation of FLAG-NDR2 are also stimulated by a relatively-limited subset of cell stress
stimuli, notably hyperosmotic shock (Fig. 3A, Fig. 4A-B) and oxidative stress (Fig. 3B-C,
Fig. 4A-B) in neonatal cardiac myocytes.  Perhaps most notably, global
ischaemia/reperfusion, a pathologically-important pro-apoptotic stress in the heart [56],
stimulates phosphorylation of NDR1(Thr-444)/NDR2(Thr-442) in isolated adult rat hearts
(Fig. 8).  Although there is a suggestion that ischaemia alone also resulted in phosphorylation
of NDR1(Thr-444)/NDR2(Thr-442), this result did not achieve statistical significance (Fig.
8).  In isolated hearts, the stress-activated protein kinases of the MAPK family are activated
(by phosphorylation) by ischaemia and ischaemia/reperfusion [57].  Thus, ischaemia activates
p38-MAPKs and this is increased on reperfusion [56,57].  Ischaemia alone does not activate
the c-Jun N-terminal kinases (JNKs), but they are activated on reperfusion [57].  However,
p38-MAPKs and JNKs are activated by a wider range of cellular stresses (e.g. anisomycin) in
cardiac myocytes than those that lead to phosphorylation of NDR1(Thr-444)/NDR2(Thr-442)
(Supplementary Material, Table 2A) or activation of FLAG-NDR2 (Supplementary Material,
Table 2B), and they are also activated by some G protein receptor agonists, e.g. ET-1 and
phenylephrine [58-60].  As with phosphorylation of NDR1(Thr-444)/NDR2(Thr-442) and
activation of FLAG-NDR2 (Fig. 3B-C, Fig. 4A-B), JNKs and p38-MAPKs are activated by
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oxidative stress in cardiac myocytes and the perfused heart [30,61], and our findings indicate
that the increases in oxidative stress that the heart experiences during ischaemia and, more
particularly, on reperfusion [62] contribute to their activation [30].  A similar mechanism
could apply to the NDRs.
4.6.  Subcellular localisation of NDR2
The subcellular localisation of the NDRs as assessed by either immunofluorescence or
subcellular fractionation is controversial.  NDR1 was first thought to be localised to the
nucleus [5].  Tagged NDR1 overexpressed in HeLa cells also appears to localise primarily to
the nucleus with evidence of an additional cytoplasmic localisation at higher levels of
expression [4].  Somewhat surprisingly in view of the similarity in their primary sequences
(see Supplementary Material, Fig. 1),  endogenous or overexpressed tagged NDR2 appears to
localise primarily to the cytoplasm (sometimes in a punctate manner) with evidence of
nuclear localisation or perinuclear concentration when expression at higher levels [3,4]. 
However, Hergovich et al. [16] (see also Reference [10]) have now demonstrated that both
endogenous NDR1 and overexpressed NDR1 are primarily cytoplasmic and suggest that
some previous studies demonstrating a nuclear localisation resulted from misinterpretation of
immunofluorescence data.  In our hands, FLAG-NDR2 expressed ectopically to about the
same level as total endogenous NDRs localises to the cytoplasm of cardiac myocytes, though
there is some evidence of increased concentration at the plasma membrane (Fig. 7).  This
might perhaps be in keeping with the need for NDR2, on association with MOB proteins, to
translocate to the plasma membrane for activation by phosphorylation [11,16].  We did not
assess the localisation of NDR1.
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4.7.  NDR2-PIFtide
When protein kinases are activated by Ser-/Thr- phosphorylation, the normal tactic to
increase the level of constitutive activity is to mutate the Ser-/Thr- residues to Asp- or Glu-. 
However, mutation of NDR1(Ser-281) does not affect activity and mutation of NDR1(Thr-
444) caused only a 1.5- to 2-fold increase in activity [12].  In PKB/Akt, phosphorylation of
the homologous hydrophobic domain Ser- (Ser-472, Ser-473 or Ser-474) depending on the
isoform (,  or )] results in full activation of PKB/Akt phosphorylated on the PDK1 site in
the T loop (Thr-308 or Thr-309) [49].  Crystallographic studies show that phosphorylation of
PKB/Akt2(Ser-474) results in a disorder-to-order transition of the C helix and interaction
with PKB/Akt(PThr-309) [63].  This ordered structure can be mimicked by the hydrophobic
motif C-terminal region of PKN2 which contains the so-called PIFtide sequence which is
highly ordered [64].  In NDR2, replacement of residues 433-464 with the PKN2 PIF domain
(human PKN2 residues 969-983) produces an NDR2 species which was estimated as
possessing a 20-fold increase in activity over the wild type NDR2 and in which the T loop
phosphorylation site is phosphorylated [3].  The specific activity of tagged NDR2-PIFtide is
about 2-fold greater than that of the tagged NDR2(wild type) from COS cells treated with 1
M OKA for 60 min, and its activity might be slightly further increased by exposure of the
cells to OKA [3].  We estimate here that the activity of FLAG-NDR2-PIF-tide was about 10-
fold greater than FLAG-NDR2(wild-type) (Fig. 6), and this was still much less (about 15-
20%) than that of FLAG-NDR2(wild-type) that had been activated by 200 nM calyculin A for
20 min.  Calyculin A did not further activate FLAG-NDR2-PIFtide (Fig. 6), presumably
because Thr-442 is absent.  We were hoping that ectopic expression of the activated FLAG-
NDR2-PIFtide might cause some obvious changes in its subcellular localisation and/or
myocyte morphology.  However, we were not able to detect any such changes and a more-
detailed examination of any prospective phenotypes is currently being undertaken.
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Table 1.
Quantitative PCR primers.  Nucleotide positions in transcripts are shown in parentheses for each primer.  mRNA sequences for established genes
were obtained from the Rat Genome Database (http://rgb.mcw.edu, viewed at http://www.ncbi.nlm.nih.gov/entrez).
Gene Accession
no./probe set
Size
(bp)
Forward primer Reverse primer
NDR1 NM_001015025 176 TTCGAGGGCCTGACAGCCAG (807-826) TCAGAGACTTGACTAGGACGCAGT (960-983)
NDR2 EF444939.1 238 AGGTCATCCGTTCTTTGAGGGTGTG (1284-1308) ACGTGGGGATGGAGCCTCGCTG (1501-1522)
Gapdh NM_017008 83 GCTGGCATTGCTCTCAATGACA (1738-1759) TCCACCACCCTGTTGCTGTA (1801-1820)
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Table 2.  Potencies of PPP1/PPP2 inhibitors.
Inhibitor IC50 against Reference
PPP1 PPP2
Calyculin A 0.3 nM 0.13 nM [65]
Okadaic acid 3.4 nM 0.07 nM [65]
Microcystin LR 0.1 nM 0.1 nM [65]
Fostriecin 4 M 40 nM [66]
Tautomycetin 1.6 nM 62 nM [67]
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Figure legends
Fig. 1.  Quantitative PCR of (A) NDR2 and (B) NDR1 mRNA abundances in cardiac
myocytes exposed to endothelin-1 (ET-1).  Myocytes (4 independent preparations for NDR2,
5 independent preparations for NDR1) were exposed to 100 nM ET-1 for the times indicated
and RNA extracted.  Transcript levels were normalised to those of Gapdh, then expressed
relative to the zero-time controls.  Results are expressed as means ± SEM.  Statistical
significance versus the zero-time control: *, P<0.05; **, P<0.01 by a paired two-tailed
Student’s t test.
Fig. 2.  Phosphorylation of NDR1(Thr-444) and NDR2(Thr-442), and activation of FLAG-
NDR2 in cardiac myocytes exposed to calyculin A.  All results are expressed as means ±
SEM.  (A) Myocytes (3 independent preparations) were exposed to 200 nM calyculin A for
the times indicated and phosphorylation of NDR1(Thr-444)/NDR2(Thr-442) assessed by
immunoblotting with an anti-NDR phosphopeptide antibody.  There were no changes in the
abundances of total NDR1/NDR2.  The intensities of the NDR1(PThr-444)/NDR2(PThr-442)
signals were assessed by scanning densitometry and expressed relative to the maximum values
which occurred after either 45 or 90 min of exposure of myocytes to calyculin A, depending
on the time point at which the greater extent of phosphorylation was observed.  (B) The
dependence of NDR1(Thr-444)/NDR2(Thr-442) phosphorylation on calyculin A
concentration was assessed in myocytes (4 independent preparations) exposed to calyculin A
for 20 min.  The intensities of the NDR1(PThr-444)/NDR2(PThr-442) signals were assessed
as described under (A) and expressed relative to the maximum values which occurred at either
100 or 300 nM calyculin A, depending on the concentration at which the greater extent of
phosphorylation was observed.    (C) Myocytes were infected with Adv.FLAG-NDR2. 
Immunoblotting with an anti-NDR1/NDR2 antibody showed that endogenous NDR1/NDR2
and FLAG-NDR2 were expressed in approximately equal amounts.  (D) The dependence of
FLAG-NDR2 activity on calyculin A concentrations was assessed in infected myocytes (4
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independent preparations) exposed to calyculin A for 20 min.  Activities were expressed
relative to the maximum values which occurred at either 100 or 300 nM calyculin A,
depending on the concentration at which the greater activity was observed.
Fig. 3.  Phosphorylation of NDR1(Thr-444) and NDR2(Thr-442) in cardiac myocytes exposed
to hyperosmotic shock or oxidative stress.  All results are expressed as means ± SEM.  (A and
B) Myocytes (3 independent preparations) were exposed to hyperosmotic shock (0.5 M
sorbitol) (A) or 0.5 mM H2O2 (B) and phosphorylation of NDR1(Thr-444)/NDR2(Thr-442)
assessed by immunoblotting with an anti-NDR phosphopeptide antibody.  There were no
changes in the abundances of total NDR1/NDR2.  The intensities of the NDR1(PThr-
444)/NDR2(PThr-442) signals were assessed by scanning densitometry and were expressed
relative to the maximum values which occurred after either 10 or 20 min of exposure of
myocytes to hyperosmotic shock (A) or 20 or 45 min of exposure to 0.5 mM H2O2 (B),
depending on the time point at which the greater extent of phosphorylation was observed.  (C)
The dependence of NDR1(Thr-444)/NDR2(Thr-442) phosphorylation on H2O2 concentration
was assessed in myocytes (5 independent preparations) exposed to H2O2  for 20 min.  The
intensities of the NDR1(PThr-444)/NDR2(PThr-442) signals were assessed as described
under (A and B) and were expressed relative to the maximum values which occurred at 0.5
mM H2O2.
Fig. 4.  Direct comparison of induction of phosphorylation of NDR1(Thr-444) and
NDR2(Thr-442), and activation of FLAG-NDR2 in cardiac myocytes exposed to a range of
interventions.  HOS, hyperosmotic shock; OKA, okadaic acid.  (A) Myocytes (3 to 8
independent preparations) were exposed to NDR modulators at the concentrations and for the
times indicated and phosphorylation of NDR1(Thr-444)/NDR2(Thr-442) assessed by
immunoblotting with an anti-NDR phosphopeptide antibody.  The intensities of the
NDR1(PThr-444)/NDR2(PThr-442) signals were assessed by scanning densitometry.  Results
are expressed relative to maximum phosphorylation which was observed with 200 nM
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calyculin A at either 20 min or 60 min, depending on the time point at which the greater
extent of phosphorylation was observed, and are means ± SEM.  Statistical significance:  *,
P<0.05; **, P<0.01, ***, P<0.001 versus control or †, P<0.01 versus OKA (1 M, 60 min)
by a 1-tailed ANOVA with Tukey’s multiple comparison test.  (B and C)  FLAG-NDR2
activity following exposure of myocytes [8 independent preparations in (B), 3 independent
preparations in (C)] to the interventions indicated and expressed relative to the maximum
activity which was observed with 200 nM calyculin A at either 20 min or 60 min, depending
on the time point at which the greater activity was observed.  Results are means ± SEM.  (D)
Myocytes expressing the FLAG-NDR2 transgene (2 independent preparations of myocytes)
were exposed to NDR modulators at the concentrations and for the times indicated and
phosphorylation of NDR1(Thr-444)/NDR2(Thr-442) assessed by immunoblotting with an
anti-NDR phosphopeptide antibody.  The intensities of the NDR1(PThr-444)/NDR2(PThr-
442) signals were assessed as under (A).  The upper band represents FLAG-NDR2(PThr-442)
and the two lower bands represent NDR1(PThr-444)/NDR2(PThr-442).  The unfilled bars in
the histogram represent FLAG-NDR2(PThr-442) whereas the filled bars represent
endogenous NDR1(PThr-444)/NDR2(PThr-442).   Results are expressed relative to maximum
phosphorylation which was observed with 200 nM calyculin A at 60 min and are means ± SD.
Fig. 5.  Inhibition of calyculin A-induced activation of FLAG-NDR2 and phosphorylation of
endogenous NDR1(Thr-444)/NDR2(Thr-442) and FLAG-NDR2(Thr-442) by staurosporine. 
Adv, adenoviral vector.  (A and B) Myocytes were preincubated for 20 min with staurosporine
at the concentrations indicated, then were exposed to 50 nM calyculin A for a further 20 min. 
(A) Inhibition of calyculin A-induced stimulation of FLAG-NDR2 activity by staurosporine. 
FLAG-NDR2 activity in control 1 was assessed at 50 nM calyculin A (20 min) in the absence
of staurosporine and results were expressed relative to this.  FLAG-NDR2 activity in control 2
was assessed in the absence of 50 nM calyculin A and staurosporine.  (B)  Inhibition of
calyculin A-induced phosphorylation of endogenous NDR1(Thr-444)/NDR2(Thr-442) (left
hand immunoblot panel and unfilled bars), and of endogenous NDR1(Thr-444)/NDR2(Thr-
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442) and FLAG-NDR2(Thr-442) (right hand immunoblot panel and filled bars) was assessed
by immunoblotting with an anti-NDR phosphopeptide antibody.  Intensities of the endogenous
NDR1(PThr-444)/NDR2(PThr-442) signals (left hand immunoblot panel) or endogenous
NDR1(PThr-444)/NDR2(PThr-442) + FLAG-NDR2(PThr-442) (right hand immunoblot
panel) were quantified by scanning densitometry and expressed relative to the values obtained
with calyculin A (50 nM, 20 min) for each single experimental grouping.  Results are means ±
SEM for 3 (A) or 4 (B) independent preparations of myocytes.
Fig. 6.  Stimulation of NDR2 activity in the FLAG-NDR2-PIFtide chimera.  Myocytes were
infected with an adenovirus (Adv) empty vector, with Adv.FLAG-NDR2(wild-type) or with
Adv.FLAG-NDR2-PIFtide.  The relative levels of expression of FLAG-NDR2(wild-type) and
FLAG-NDR2-PIFtide were assessed with an antibody to the FLAG epitope (upper panel). 
Myocytes expressing the transgenes were exposed to 200 nM calyculin A for 20 min and the
activities of FLAG-NDR2(wild type) or FLAG-NDR2-PIFtide were measured (lower panel). 
Results are expressed relative to the FLAG-NDR2(wild-type) infected myocytes exposed to
200 nM calyculin A for 20 min and are means ± SEM for 6 independent preparations of
myocytes.  The results shown were not corrected for expression levels and the Adv blank was
not subtracted (but see the Results section for these calculations).
Fig. 7.  Subcellular localisation of FLAG-NDR2.  Myocytes were infected with Adv.FLAG-
NDR2 and were stained with (A) monoclonal anti-FLAG, (B) phalloidin, or (C) Hoechst
33258 and a representative image of a single field is shown.
Fig. 8.  Phosphorylation of NDR1(Thr-444)/NDR2(Thr-442) in intact hearts.  In each separate
set of experiments, following a 15 min retrograde stabilisation perfusion, ex vivo rat heart
preparations were either (i) perfused retrogradely for a further 20 min, (ii) rendered globally-
ischemic for 10 min by occlusion of the aortic inflow, (iii) reperfused retrogradely for 10 min
following global ischaemia (10 min), or (iv) perfused retrogradely with 40 nM calyculin A for
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5 min.  Phosphorylation of NDR1(Thr-444)/NDR2(Thr-442) was assessed by immunoblotting
with an anti-NDR phosphopeptide antibody, and intensities of the NDR1(PThr-
444)/NDR2(PThr-442) signals were quantified by scanning densitometry and expressed
relative to the values obtained with perfusions with calyculin A (40 nM, 5 min) for each single
experimental grouping.  Results are means ± SEM for 8 complete sets of experiments. 
Statistical significance versus the control perfusions: *, P<0.0001 versus control by an
unpaired two-tailed Student’s t test.
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Supplementary material
Sequencing of rat NDR2 mRNA
Mouse NDR2 mRNA (Genbank accession no. NM_172734.2) was used to search the
rat genome (www.ncbi.nlm.nih.gov/BLAST/) for the orthologous rat NDR2.  Because of the
incompleteness of the rat genomic sequence, only a partial sequence was identified on rat
chromosome 4.  Mouse NDR2 mRNA was then used to search for expressed sequence tags
(ESTs) allocated to that region of rat chromosome 4 (Genbank accession nos. CV126295.1,
CB720056.1, CB611889.1, CO568629.1, CV126546.1, BI290748.1 and CB801811.1).  By
combining sequences from the rat genome and these ESTs, the nucleotides comprising
1-1258 bp of the open reading frame of rat NDR2 mRNA were obtained.  The last 336 bp of
mouse NDR2 mRNA open reading frame were used to search against rat genome ESTs, and
two additional ESTs were identified (Genbank accession nos. CV126295.1 and
CB771034.1).  Following this in silico approach, 1-1258bp and 1293-1592bp were obtained
for rat NDR2 mRNA.  cDNA prepared from neonatal rat ventricular myocytes was used as a
template for PCR amplification with sets of primers (spanning predicted exon-exon
boundaries) based on the in silico sequence (Supplementary Material, Table 1A).  The
resulting RT-PCR products were detected by SYBR green staining of agarose gel
electrophoretograms and the bands captured under UV illumination.  Bands were excised
from the gel and purified using QIAQUICK spin columns.  The sequence of PCR product
with each primer pair was verified by automated sequencing with the indicated (Table 1B)
primers (Advanced Biotechnology Centre, Imperial College London) using an ABI 3100
Genetic Analyser.  PCR products were sequenced from both ends with the primers originally
used for PCR.
Rapid amplification of cDNA ends (RACE) analysis
Total RNA was extracted using RNA-Bee from 3 separate myocyte preparations. 
Quantity and purity of RNAs were assessed from the A260 and the A260/A280 ratio (1.8-2.0). 
Total RNA (150 :g) from control or endothelin-1 (ET-1, 100 nM, 2 h) treated myocytes was
used for poly(A)+ RNA purification with oligo dT-cellulose (Biochemica, distributed by
Sigma-Aldrich Company Ltd., U.K.).  Briefly, total RNA dissolved in deionised water (600
:l) was incubated for 5 min at 65°C followed by addition of 1 vol. of 2 × Binding Buffer [1
M NaCl, 20 mM Tris pH 7.5, 2 mM EDTA, 0.1% (w/v) SDS].  Oligo dT-cellulose (5 mg) in
100 :l Binding Buffer was added and mixtures were rotated in room temperature for 15 min. 
The oligo dT-cellulose was washed twice with Binding Buffer (1 ml) and twice with
Washing Buffer [1 ml; 0.2 M NaCl, 10 mM Tris pH 7.5, 1 mM EDTA, 0.05 % (w/v) SDS]. 
Poly(A)+ RNA was eluted from the oligo dT-cellulose by incubation (2 × 5 min, 37°C) in
Elution Buffer [250 :l; 10 mM Tris pH 7.5, 1 mM EDTA, 0.05% (w/v) SDS].  The
purification procedure was repeated and poly(A)+ RNA was precipitated with 4 M NaCl (50
:l) and two vol. absolute ethanol, followed by centrifugation (10,000 × g, 15 min, 4°C). 
After washing with 70% (v/v) ethanol and repeated centrifugation, poly(A)+ RNA was
dissolved in deionised water (8 :l).  Poly(A)+ RNA was reverse-transcribed using a
SMART™ RACE cDNA Amplification Kit (Clontech).  Poly(A)+ RNA (0.9 :g) was mixed
with 10 mM oligo-dT primer (1 :l, 5'-CDS primer A or 3'-CDS primer A), 10 mM
SMART™ II A oligonucleotide (1 :l), and deionised water to a total volume of 5 :l.  The
reaction mixture was heated (2 min, 72°C) and cooled on ice.  Subsequently, 5 × Reaction
Buffer (2 :l; 250 mM Tris-HCl, pH 8.3, 30 mM MgCl2, 375 mM KCl), 10 mM dNTP (1 :l ),
20 mM dithiothreitol (DTT, 1 :l) and PowerScript™ reverse trancriptase (1 :l) were added
and mixture was incubated at 42/C for 90 min.  Reverse transcriptase was then inactivated
(72°C, 7 min).  RACE cDNA reaction mixture (10 :l) was diluted to 250 :l with
Tricine-EDTA (10 mM Tricine pH 8.5, 1 mM EDTA) and stored at -80°C.  Sequence
corresponding to either 5'-end or 3'-end of NDR2 mRNA were amplified using SMART™
RACE cDNA Amplification Kit's Universal Primer A Mix (UPM, complementary for the
extended 5'-end of the 5'-RACE cDNA or extended of 3'-end of 3'-RACE cDNA after the
poly-A tail) and NDR2 gene specific primers.  For each PCR reaction, 2.5 :l of RACE
cDNA was combined with 10 × Advantage® 2 Polymerase Buffer [Clontech, 10 :l; 40 mM
Tricine-KOH pH 9.2, 15 mM KOAc, 3.5 mM Mg(OAc)2], NDR2 gene specific primer (1 :l;
10 :M), 10 × UPM (5 :l), dNTP (10 mM) and Advantage® 2 Polymerase Mix (1 :l).  The
polymerase chain reaction (PCR) program was as follows: 94°C, 5min; 5 cycles of (94°C, 30
s; 72°C, 2 min), 5 cycles of (94°C, 30 s; 70°C, 30 s; 72°C, 2 min), 25 cycles (94°C, 30 s;
68°C, 30 s; 72°C, 2 min) and 72°C, 4 min.  The PCR reaction mixture was diluted 1:50 with
MilliQ water and the diluted RACE reaction (2.5 :l) was used as a template in nested PCR
with appropriate NDR2 primers (Supplementary Material, Table 1C) and the SMART™
RACE cDNA Amplification Kit Nested UPM primer using a similar PCR protocol as in
original RACE PCR.  Nested PCR products were analysed on SYBR Green-stained agarose
gels and the bands were captured under UV illumination.  Products were excised from the gel
and purified using QIAQUICK PCR purification columns for automated sequencing
(Advanced Biotechnology Centre, Imperial College London) using an ABI 3100 Genetic
Analyser.  The ClustalW program (www.ebi.ac.uk/clustalw) was used for multiple alignment
of sequencing results (Supplementary Material, Fig. 1), and the rat NDR2 mRNA sequence
submitted to Genbank (accession no. EF444939.1).
Adenoviral vectors  
Adenoviral vectors were prepared using the AdEasy™ XL Adenoviral Vector System
(Stratagene).  To facilitate identification, separation and immunoprecipitation of virally
infected proteins from endogenous NDR2, adenoviral constructs were tagged with a FLAG®
sequence (DYKDDDDK) at their N-terminus.  A FLAG® sequence was first introduced
between the BglII and KpnI restriction sites in the multiple cloning site (MCS) of the
pShuttle-CMV vector by synthesis of an oligonucleotide cassette containing the FLAG
sequence preceded by an ATG start codon.  The complementary oligonucleotides used were:
Forward:
5'-GATCTACCATGGACTACAAAGACGATGACGACAAGGGTACCGTCGACGC-3';
Reverse:
5'-GGCCGCGTCGACGGTACCCTTGTCGTCATCGTCTTTGTAGTCCATGGTA-3' with the
FLAG® sequence underlined and emboldened and its antisense complement underlined and
italicised.  The oligonucleotides were annealed and phosphorylated, resulting in a cassette
flanked by "cut" BglII and NotI sites, which was then inserted into the corresponding
restriction sites in the multiple cloning site of pShuttle-CMV.  This strategy, which replaces
the KpnI-NotI fragment of pShuttle-CMV with an identical sequence in the cassette insert,
was used to avoid the potential difficulty of cutting both the BglII and KpnI sites which lie
immediately adjacent to each other in pShuttle-CMV.
The rat NDR2 coding sequence was subsequently amplified from rat cDNA by PCR
with Pfu polymerase using forward primer
(5'-GACGACAAGGGTACCATGGCAATGACGGCAGGGGC-3') and reverse primer
(5'-CTTATCTAGAAGCTTTCATAACTTCCCAGCTTTC-3') to produce NDR2 flanked by
KpnI (forward primer) and HindIII (reverse primer) sites which are underlined and
emboldened.  These were then used for insertion into the corresponding sites in the prepared
FLAG-pShuttle-CMV, downstream and in frame with the FLAG tag sequence.  NDR2PIF
was prepared similarly but using reverse primer
5'-CTTATCTAGAAGCTTTCACCAGTCGGCGATGTAGTCGAAGTCGCGGAACATCT
CCTGCTCCTCTTTGTAGTCAGGCTCTGTGGTATTCG-3' which generates a product in
which the C-terminal hydrophobic domain of NDR2 (residues 433-464) is replaced with the
3-phosphoinositide-dependent kinase 1 interacting fragment (PIF) of human protein kinase
N2 (PKN2, NP_006247 residues 969-983, sequence EQEMFRDFDYVADW), as has been
previously performed for human NDR2 [1].  The orthologous sequence in rat PKN2 is
identical to human PKN2 except for the substitution of Ile- for Val-980.  All constructs were
sequenced using an ABI 3100 Genetic Analyser (Advanced Biotechnology Centre, Imperial
College London).  Shuttle plasmids containing verified sequences were then linearised with
PmeI and used to transform BJ5183-AD-1 cells which were subsequently screened for
homologous recombination.  Adenoviral plasmids from positive recombinants were expanded
in XL10Gold cells, linearised with PacI and used to transform HEK293 cells, as described in
the AdEasy™ XL Adenoviral Vector System manual.  Viruses were amplified through
subsequent re-infection of HEK293 cells.
Reference
 [1]  M.R. Stegert, R. Tamaskovic, S. J. Bichsel, A. Hergovich, B. A. Hemmings, J. Biol.
Chem. 279 (2004) 23806.
SUPPLEMENTARY MATERIAL TABLE 1.  Primer sequences. 
 
A.  Sequences for RT-PCR of NDR2 mRNA 
 
 
Primer 
 
 
 
Sequence (5´Æ3´) 
 
Position in NDR2 
(EF444939.1) 
 
Primer pairing 
 
 
F1 
 
TGGCAATGACGGCAGGGGCAAC 
 
152Æ173 
 
F1R1, F1R2 
R1  TCCTCGTCTGCCAGTCCTTC 316Å336 F1R1 
R2  TTCTCCTCGTCTGCCAGTCC 319Å338 F1R2 
F2  ACTGTGGCCAAGCTCACGCTG 214Æ234 F2R3 
R3  TGGCATAGATGTGCCCTGTG 483Å502 F2R3 
F3  TGTGGCCAAGCTCACGCTGG 216Æ235 F3R4 
R4  TCATGGCATAGATGTGCCCT 486Å505 F3R4 
F4  AGAAGGACTGGCAGACGAGG 315Æ334 F4R5 
R5  CTGAGATGTAGAACTGCGTC 717Å736 F4R5 
F5, CAGGTGGCTCATATCCGAGC 541Æ560 F5R6, F5R7, F5R8 
R6  AGCCTAGCTGGTGGATTGCGTC 754Å775 F5R6 
F7  ACACCAGACTACATTGCTCCAGAGG 1006Æ1030 F5R7 
R8  AAGTCCTTGGCTTTCTCAGAGACG 1197Å1220 F5R8 
F8  TGGCATTTCCTCCAGAGGTGC, 1175Æ1195 F8R9, F8R10 
R9  TGGAGCCTCGCTGGGTCAGC 1494Å1513 F8R9, F8R10 
F9  AGGTCATCCGTTCTTTGAGGGTGTG 1284Æ1308 F9R10 
R10  ACGTGGGGATGGAGCCTCGCTG 1501Å1522 F8R10, F9R10 
    
 
 
 
 
 
 
B. Primers for NDR2 sequencing 
 
 
Primer 
 
Sequence (5´Æ3´) 
 
Position in 
NDR2 
(EF444939.1) 
 
 
F14 
 
AGGTCATCCGTTCTTTGAGGGTG 
 
1284Æ1306 
R15 AGGTTCTACAGGCAGCTTTCATGG 2379Æ2356 
F15 TCCGGAGCATAGATGACACCTCA 1355Æ1377 
R14 ACGCACTAGGTAGGTTCTACAGGCAG 2365Å2390 
R15  AGGTTCTACAGGCAGCTTTCATGG 2356Æ2379 
F16 
 
CACATCGCACTGATGGCACC 1896Æ1915 
 
C. Primer sequences for NDR2 RACE 
 
 
Primer 
 
Sequence (5´Æ3´) 
 
Position in 
NDR2 
(EF444939.1) 
 
 
Function 
 
F10  
 
ACGCAATCCACCAGCTAGGCTTCATCCACCGGGA 
 
755Æ788 
 
3´-RACE 
F11 AGACGCTGGCATTTCCTCCAGAGGTGCCCGT 1169Æ1199 3´-RACE, Nested PCR for F10 product 
F12  GGTTTGAAGGGCTGACCCAGCGAGGCTCCATCC 1484Æ1516 3´-RACE, Nested PCR for F11 product 
R11 TGGACCAGCCGCACCTCTCCGAAAGCTCCTC 443Å473 5´-RACE, Nested PCR for R12 product 
R12 TCCCGGTGGATGAAGCCTAGCTGGTGGATTGCGTC 754Å788 5´-RACE, Nested PCR for R13 product 
R13 
 
AGACGGGCACCTCTGGAGGAAATGCCAGCGTC 1170Å1201 5´-RACE 
 
 
SUPPLEMENTARY MATERIAL TABLE 2.  Agonists and interventions ineffective in causing
phosphorylation of endogenous NDR1/NDR2  or activation of FLAG-NDR2.
A.  Agonists and interventions tested which did not increase phosphorylation of NDR1(Thr-
444)/NDR2(Thr-442).
Endothelin-1 (100 nM, vasoactive peptide, pro-hypertrophic agonist in cardiac myocytes)
Tumor necrosis factor " (10 ng/ml, pro-inflammatory cytokine)
Interleukin 1$ (10 ng/ml, pro-inflammatory cytokine)
Leukemia inhibitory factor (10 nU/ml, gp130-linked cytokine receptor agonist)
Cardiotrophin-1 (1 nM, gp130-linked cytokine receptor agonist, pro-hypertrophic agonist in cardiac
myocytes)
Ionomycin (1 :M)
A23187 (20 :M, Ca2+ ionophore)
Anisomycin (50 ng/ml, protein synthesis inhibitor, cytotoxic stressor)
Cycloheximide (20 :M, protein synthesis inhibitor, cytotoxic stressor)
Staurosporine (1 :M, generalized Ser-/Thr-protein kinase, pro-apoptotic in cardiac myocytes)
Cyclosporin A [1 :M, phosphoprotein phosphatase 3 (calcineurin) inhibitor]
Doxorubicin (5 :M, antineoplastic anthracycline, pro-apoptotic in cardiac myocytes and
cardiomyopathic)
Insulin (300 nM, receptor protein tyrosine kinase agonist polypeptide)
Platelet-derived growth factor (20 ng/ml, receptor protein tyrosine kinase agonist polypeptide)
Epidermal growth factor  (20 ng/ml, receptor protein tyrosine kinase agonist polypeptide)
Phorbol 12-myristate 13-acetate (1 :M, activator of classical and novel isoforms of protein kinase C,
pro-hypertrophic agonist in cardiac myocytes)
Phenylephrine (100  :M, "-adrenergic receptor agonist,  pro-hypertrophic agonist in cardiac myocytes)
B. Agonists and agents tested which did not increase the activity of FLAG-tagged NDR2.
Na arsenite (0.5 mM, cytotoxic stressor)
Cycloheximide (20 :M, protein synthesis inhibitor, cytotoxic stressor)
Isoproterenol (10 :M, $-adrenergic receptor agonist, positive inotrope, lusitrope and chronotrope)
Phenylephrine (10  :M, "-adrenergic receptor agonist,  pro-hypertrophic agonist in cardiac myocytes)
Norepinephrine (10 :M, "-/$-adrenergic receptor agonist,  pro-hypertrophic agonist in cardiac
myocytes)
Endothelin-1 (100 nM, vasoactive peptide, pro-hypertrophic agonist in cardiac myocytes)
KCl (40 mM, cardioplegic intervention)
pH6.6 or pH 7.8 (pH lowered from or raised above control value of 7.4)
Lipopolysaccharides from Escherichia coli 0111.B4 or from Salmonella typhimurium serotype
minnesota (500 ng/ml, endotoxin/cytotoxic stressors)
Lipopolysaccharides (rough strains) from Salmonella typhimurium serotype minnesota Re 595 (500
ng/ml, endotoxin/cytotoxic stressor)
SUPPLEMENTARY MATERIAL FIG. 1.  Alignments are shown for the amino acid
sequences encoded by the rat NDR2 (rNDR2, EF444939.1) cDNA, human NDR1 (hNDR1,
NP_009202.1), mouse NDR1 (mNDR1, NP_598876.1),  the predicted sequence for rNDR1
(genomic contig Rn20_WGA2119_4), hNDR2 (NP_055815.1) and mNDR2 (NP_766322.1). 
The peptide sequences to which the hNDR1 antibody was raised (59-86) and to which the
hNDR1(PThr-444) antibody was raised (436-450) are emboldened and underlined.
rNDR2 MAMTAGATTT FPMSSHTRER VTVAKLTLEN FYSNLILQHE ERETRQKKLE VAMEEEGLAD 60
mNDR2 MAMTAGATTT FPMSNHTRER VTVAKLTLEN FYSNLILQHE ERETRQKKLE VAMEEEGLAD 60
hNDR2 MAMTAGTTTT FPMSNHTRER VTVAKLTLEN FYSNLILQHE ERETRQKKLE VAMEEEGLAD 60
rNDR1 MAMT-GSTPC SSMSNHTKER VTMTKVTLEN FYSNLIAQHE EREMRQKKLE KVMEEEGLKD 59
mNDR1 MAMT-GSTPC SSMSNHTKER VTMTKVTLEN FYSNLIAQHE EREMRQKKLE KVMEEEGLKD 59
hNDR1 MAMT-GSTPC SSMSNHTKER VTMTKVTLEN FYSNLIAQHE EREMRQKKLE KVMEEEGLKD 59
**** .:*.   .**.**:** **::*:**** ****** *** *** ******  .****** *
rNDR2 EEKKLRRSQH ARKETEFLRL KRTRLGLDDF ESLKVIGRGA FGEVRLVQKK DTGHIYAMKI 120
mNDR2 EEKKLRRSQH ARKETEFLRL KRTRLGLDDF ESLKVIGRGA FGEVRLVQKK DTGHIYAMKI 120
hNDR2 EEKKLRRSQH ARKETEFLRL KRTRLGLDDF ESLKVIGRGA FGEVRLVQKK DTGHIYAMKI 120
rNDR1 EEKRLRRSAH ARKETEFLRL KRTRLGLEDF ESLKVIGRGA FGEVRLVQKK DTGHVYAMKI 119
mNDR1 EEKRLRRSAH ARKETEFLRL KRTRLGLEDF ESLKVIGRGA FGEVRLVQKK DTGHVYAMKI 119
hNDR1 EEKRLRRSAH ARKETEFLRL KRTRLGLEDF ESLKVIGRGA FGEVRLVQKK DTGHVYAMKI 119
***:**** * ********** *******:** ********** ********** ****:*****
rNDR2 LRKADMLEKE QVAHIRAERD ILVEADGAWV VKMFYSFQDK RNLYLIMEFL PGGDMMTLLM 180
mNDR2 LRKADMLEKE QVAHIRAERD ILVEADGAWV VKMFYSFQDK RNLYLIMEFL PGGDMMTLLM 180
hNDR2 LRKSDMLEKE QVAHIRAERD ILVEADGAWV VKMFYSFQDK RNLYLIMEFL PGGDMMTLLM 180
rNDR1 LRKADMLEKE QVGHIRAERD ILVEADSLWV VRMFYSFQDK LNLYLIMEFL PGGDMMTLLM 179
mNDR1 LRKADMLEKE QVGHIRAERD ILVEADSLWV VKMFYSFQDK LNLYLIMEFL PGGDMMTLLM 179
hNDR1 LRKADMLEKE QVGHIRAERD ILVEADSLWV VKMFYSFQDK LNLYLIMEFL PGGDMMTLLM 179
***:****** **.******* ******. ** **********  ********* **********
rNDR2 KKDTLTEEET QFYISETVLA IDAIHQLGFI HRDIKPDNLL LDAKGHVKLS DFGLCTGLKK 240
mNDR2 KKDTLTEEET QFYISETVLA IDAIHQLGFI HRDVKPDNLL LDAKGHVKLS DFGLCTGLKK 240
hNDR2 KKDTLTEEET QFYISETVLA IDAIHQLGFI HRDIKPDNLL LDAKGHVKLS DFGLCTGLKK 240
rNDR1 KKDTLTEEET QFYIAETVLA IDSIHQLGFI HRDIKPDNLL LDSKGHVKLS DFGLCTGLKK 239
mNDR1 KKDTLTEEET QFYIAETVLA IDSIHQLGFI HRDIKPDNLL LDSKGHVKLS DFGLCTGLKK 239
hNDR1 KKDTLTEEET QFYIAETVLA IDSIHQLGFI HRDIKPDNLL LDSKGHVKLS DFGLCTGLKK 239
********** ****:***** **:******* ***:****** **:******* **********
rNDR2 AHRTEFYRNL THNPPSDFSF QNMNSKRKAE TWKKNRRQLA YSTVGTPDYI APEVFMQTGY 300
mNDR2 AHRTEFYRNL THNPPSDFSF QNMNSKRKAE TWKKNRRQLA YSTVGTPDYI APEVFMQTGY 300
hNDR2 AHRTEFYRNL THNPPSDFSF QNMNSKRKAE TWKKNRRQLA YSTVGTPDYI APEVFMQTGY 300
rNDR1 AHRTEFYRNL NHSLPSDFTF QNMNSKRKAE TWKRNRRQLA FSTVGTPDYI APEVFMQTGY 299
mNDR1 AHRTEFYRNL NHSLPSDFTF QNMNSKRKAE TWKRNRRQLA FSTVGTPDYI APEVFMQTGY 299
hNDR1 AHRTEFYRNL NHSLPSDFTF QNMNSKRKAE TWKRNRRQLA FSTVGTPDYI APEVFMQTGY 299
********** .*. ****:* ********** ***:****** :********* **********
rNDR2 NKLCDWWSLG VIMYEMLIGF PPFCSETPQE TYRKVMSWKE TLAFPPEVPV SEKAKDLILR 360
mNDR2 NKLCDWWSLG VIMYEMLIGF PPFCSETPQE TYRKVMSWKE TLAFPPEVPV SEKAKDLILR 360
hNDR2 NKLCDWWSLG VIMYEMLIGY PPFCSETPQE TYRKVMNWKE TLVFPPEVPI SEKAKDLILR 360
rNDR1 NKLCDWWSLG VIMYEMLIGY PPFCSETPQE TYKKVMNWKE TLTFPPEVPV SEKAKGLILR 359
mNDR1 NKLCDWWSLG VIMYEMLIGY PPFCSETPQE TYKKVMNWKE TLTFPPEVPV SEKAKGLILR 359
hNDR1 NKLCDWWSLG VIMYEMLIGY PPFCSETPQE TYKKVMNWKE TLTFPPEVPI SEKAKDLILR 359
********** *********: ********** **:***.*** **.******: *****.****
rNDR2 FCTDSENRIG NGGVEEIKGH PFFEGVDWGH IRERPAAIPI EIRSIDDTSN FDDFPESDIL 420
mNDR2 FCTDSENRIG NGGVEEIKGH PFFEGVDWGH IRERPAAIPI EIRSIDDTSN FDDFPESDIL 420
hNDR2 FCIDSENRIG NSGVEEIKGH PFFEGVDWEH IRERPAAIPI EIKSIDDTSN FDDFPESDIL 420
rNDR1 FCCEWEHRIG APGVEEIKSN PFFEGVDWEH IRERPAAISI EIKSIDDTSN FDEFPESDIL 419
mNDR1 FCCEWEHRIG APGVEEIKNN LFFEGVDWEH IRERPAAISI EIKSIDDTSN FDEFPESDIL 419
hNDR1 FCCEWEHRIG APGVEEIKSN SFFEGVDWEH IRERPAAISI EIKSIDDTSN FDEFPESDIL 419
** : *:***   ******.:  ******* * ********.* **:******* **:*******
rNDR2 QPVPNTT--- EPDYKSKDWV FLNYTYKRFE GLTQRGSIPT YMKAGKL 464
mNDR2 QPVPNTT--- EPDYKSKDWV FLNYTYKRFE GLTQRGSIPT YMKAGKL 464
hNDR2 QPVPNTT--- EPDYKSKDWV FLNYTYKRFE GLTQRGSIPT YMKAGKL 464
rNDR1 KPTVTTSNHP ETDYKSKDWV FINYTYKRFE GLTARGAIPS YMKAAK 465
mNDR1 KPTVTTSSHP ETDYKNKDWV FINYTYKRFE GLTARGAIPS YMKAAK 465
hNDR1 KPTVATSNHP ETDYKNKDWV FINYTYKRFE GLTARGAIPS YMKAAK 465
:*.  *:    *.***.**** *:******** *** **:**: ****.*:
